Display options
Share it on

BMJ Open Gastroenterol. 2015 Nov 02;2(1):e000038. doi: 10.1136/bmjgast-2015-000038. eCollection 2015.

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination.

BMJ open gastroenterology

Lise Tornvig Erikstrup, Mie Aarup, Rikke Hagemann-Madsen, Frederik Dagnaes-Hansen, Brian Kristensen, Katharina Elisabeth Pribil Olsen, Kurt Fuursted

Affiliations

  1. Department of Clinical Microbiology , Aarhus University Hospital , Aarhus , Denmark ; Institute of Clinical Medicine, Aarhus University , Aarhus , Denmark.
  2. Department of Clinical Microbiology , Aarhus University Hospital , Aarhus , Denmark ; Department of Biomedicine , Aarhus University , Aarhus , Denmark.
  3. Department of Clinical Pathology , Vejle Hospital , Vejle , Denmark.
  4. Department of Biomedicine , Aarhus University , Aarhus , Denmark.
  5. Department of Microbiology and Infection Control , Statens Serum Institute , Copenhagen , Denmark.

PMID: 26568840 PMCID: PMC4641438 DOI: 10.1136/bmjgast-2015-000038

Abstract

OBJECTIVE: Clostridium difficile is a major cause of nosocomial infectious diarrhoea. Treatment of C. difficile infection (CDI) depends on disease severity. A combination of vancomycin and metronidazole is often recommended in severe cases. The aim of this study was to examine, in a murine model of CDI, if mice treated with a combination of vancomycin and metronidazole had a better clinical outcome than mice treated with vancomycin or metronidazole alone.

DESIGN: C57BL/6J mice pretreated with an antimicrobial mixture were challenged with C. difficile VPI 10463 or phosphate-buffered saline by oral gavage. After the challenge, the mice were treated with placebo, vancomycin, metronidazole or a combination of vancomycin and metronidazole for 10 days. The mice were monitored for 20 days with weight and a clinical score. Stool samples were examined for C. difficile spore load and presence of C. difficile toxins.

RESULTS: None of the mice in the vancomycin-treated group died during the treatment phase compared to a mortality of 17%, 33% and 55% in the combination, metronidazole and infected control group, respectively. Mice treated with vancomycin alone or in combination with metronidazole recovered from CDI faster than mice treated with metronidazole alone. However, after discontinuation of treatment, vancomycin-treated and combination-treated mice succumbed to clinical and bacteriological relapse.

CONCLUSIONS: Mice treated with vancomycin alone had a better clinical outcome in the treatment phase of CDI than mice treated with metronidazole alone. A combination of vancomycin and metronidazole did not improve the clinical outcome when compared to treatment with vancomycin alone.

TRIAL REGISTRATION NUMBER: The trial registration number from the Danish Experimental Animal Inspectorate is J number 2012-15-2934-00422.

Keywords: ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COLONIC BACTERIA; COLONIC DISEASES; INFECTIOUS DIARRHOEA

References

  1. Gut. 2013 Sep;62(9):1295-305 - PubMed
  2. Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499 - PubMed
  3. N Engl J Med. 1994 Jan 27;330(4):257-62 - PubMed
  4. Lancet. 1983 Nov 5;2(8358):1043-6 - PubMed
  5. PLoS One. 2013 Oct 02;8(10):e76269 - PubMed
  6. Clin Infect Dis. 2009 Feb 15;48(4):e41-6 - PubMed
  7. Infect Immun. 1978 Nov;22(2):418-22 - PubMed
  8. J Clin Pathol. 2011 Jan;64(1):1-5 - PubMed
  9. Clin Infect Dis. 2005 Jun 1;40(11):1591-7 - PubMed
  10. J Antimicrob Chemother. 2009 May;63(5):1076 - PubMed
  11. Infect Immun. 2011 Jul;79(7):2856-64 - PubMed
  12. Clin Infect Dis. 2006 Aug 15;43(4):421-7 - PubMed
  13. Clin Infect Dis. 2005 Jun 1;40(11):1586-90 - PubMed
  14. J Clin Gastroenterol. 2009 Jan;43(1):91-3 - PubMed
  15. BMC Infect Dis. 2010 Dec 30;10:363 - PubMed
  16. Clin Infect Dis. 2006 Sep 1;43(5):547-52 - PubMed
  17. Clin Infect Dis. 1997 Sep;25 Suppl 2:S206-10 - PubMed
  18. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26 - PubMed
  19. Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S235-41 - PubMed
  20. Gut. 1986 Oct;27(10):1169-72 - PubMed
  21. J Oncol Pharm Pract. 2014 Jun;20(3):172-82 - PubMed
  22. Antimicrob Agents Chemother. 1992 Oct;36(10):2192-6 - PubMed
  23. Clin Infect Dis. 2007 Aug 1;45(3):302-7 - PubMed
  24. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96 - PubMed
  25. Antimicrob Agents Chemother. 2012 Aug;56(8):4103-11 - PubMed
  26. J Clin Invest. 1994 Mar;93(3):1257-65 - PubMed
  27. Lancet Infect Dis. 2012 Apr;12(4):281-9 - PubMed
  28. Ann Pharmacother. 2011 Jul;45(7-8):1005-10 - PubMed
  29. J Antimicrob Chemother. 1995 Oct;36(4):673-9 - PubMed
  30. Clin Infect Dis. 2009 Jun 15;48(12):1732-5 - PubMed
  31. Ann Intern Med. 1992 Aug 15;117(4):297-302 - PubMed
  32. Gut Microbes. 2011 May-Jun;2(3):145-58 - PubMed
  33. Postgrad Med J. 1987 Nov;63(745):993-4 - PubMed
  34. Clin Infect Dis. 1996 May;22(5):813-8 - PubMed
  35. N Engl J Med. 2011 Feb 3;364(5):422-31 - PubMed
  36. J Clin Microbiol. 2011 Dec;49(12):4299-300 - PubMed
  37. Infect Control Hosp Epidemiol. 2010 May;31(5):431-55 - PubMed
  38. Gastroenterology. 2008 Dec;135(6):1984-92 - PubMed
  39. Am J Gastroenterol. 2007 Dec;102(12):2781-8 - PubMed

Publication Types